{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:42:36Z","timestamp":1789065756997,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900614"],"award-info":[{"award-number":["81900614"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejphar.2020.173570","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T01:03:21Z","timestamp":1600304601000},"page":"173570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy"],"prefix":"10.1016","volume":"887","author":[{"given":"Min","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongshuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173570_bib1","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173570_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1373\/clinchem.2007.094672","article-title":"Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria","volume":"54","author":"Cabre","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejphar.2020.173570_bib3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.cmet.2013.04.012","article-title":"Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production","volume":"17","author":"Cao","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2020.173570_bib4","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.numecd.2014.03.006","article-title":"Circulating adipocyte fatty acid binding protein is increased in chronic and acute renal dysfunction","volume":"24","author":"Ebert","year":"2014","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.ejphar.2020.173570_bib5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nm.2067","article-title":"Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis","volume":"15","author":"Erbay","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2020.173570_bib6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nature05844","article-title":"Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2","volume":"447","author":"Furuhashi","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.173570_bib7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jare.2016.09.006","article-title":"Serum uric acid and acute kidney injury: a mini review","volume":"8","author":"Hahn","year":"2017","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ejphar.2020.173570_bib8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrendo.2015.122","article-title":"Metabolic functions of FABPs-mechanisms and therapeutic implications","volume":"11","author":"Hotamisligil","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejphar.2020.173570_bib9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fphar.2018.00917","article-title":"Pharmacological inhibition of fatty acid-binding protein 4 (FABP4) protects against rhabdomyolysis-induced acute kidney injury","volume":"9","author":"Huang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173570_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ajkd.2012.07.021","article-title":"Uric acid as a target of therapy in CKD","volume":"61","author":"Jalal","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2020.173570_bib11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation","volume":"71","author":"Johnson","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2020.173570_bib12","doi-asserted-by":"crossref","first-page":"F1327","DOI":"10.1152\/ajprenal.00272.2019","article-title":"Uric acid and inflammation in kidney disease","volume":"318","author":"Jung","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2020.173570_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.kint.2017.09.033","article-title":"Renal tubule injury: a driving force toward chronic kidney disease","volume":"93","author":"Liu","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2020.173570_bib14","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1681\/ASN.2014080793","article-title":"EGF receptor inhibition alleviates hyperuricemic nephropathy","volume":"26","author":"Liu","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2020.173570_bib15","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Trans Targeted Ther"},{"key":"10.1016\/j.ejphar.2020.173570_bib16","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1053\/j.ajkd.2016.11.006","article-title":"AJKD atlas of renal pathology: gouty nephropathy","volume":"69","author":"Lusco","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2020.173570_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cmet.2004.12.008","article-title":"Adipocyte\/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes","volume":"1","author":"Maeda","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2020.173570_bib18","doi-asserted-by":"crossref","first-page":"e115429","DOI":"10.1371\/journal.pone.0115429","article-title":"Urinary excretion of fatty acid-binding protein 4 is associated with albuminuria and renal dysfunction","volume":"9","author":"Okazaki","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.173570_bib19","doi-asserted-by":"crossref","first-page":"F1151","DOI":"10.1152\/ajprenal.00034.2019","article-title":"Targeting STAT3 signaling in kidney disease","volume":"316","author":"Pace","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2020.173570_bib20","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.biopha.2018.11.022","article-title":"Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy","volume":"109","author":"Pan","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2020.173570_bib21","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.2174\/0929867326666181211094421","article-title":"Mechanistic insights of soluble uric acid-related kidney disease","volume":"27","author":"Pan","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173570_bib22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41419-019-1610-5","article-title":"FABP4 contributes to renal interstitial fibrosis via mediating inflammation and lipid metabolism","volume":"10","author":"Qiao","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2020.173570_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cmet.2007.07.008","article-title":"Blocking fatty acids\u2019 mystery tour: a therapy for metabolic syndrome?","volume":"6","author":"Roden","year":"2007","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2020.173570_bib24","doi-asserted-by":"crossref","first-page":"F116","DOI":"10.1152\/ajprenal.00160.2006","article-title":"Effect of elevated serum uric acid on cisplatin-induced acute renal failure","volume":"292","author":"Roncal","year":"2007","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2020.173570_bib25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41581-019-0174-z","article-title":"The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD","volume":"15","author":"Sato","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2020.173570_bib26","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.kint.2016.06.038","article-title":"Fyn deficiency attenuates renal fibrosis by inhibition of phospho-STAT3","volume":"90","author":"Seo","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2020.173570_bib27","doi-asserted-by":"crossref","first-page":"15207","DOI":"10.1039\/C8RA00122G","article-title":"Pharmacological inhibition of fatty acid-binding protein 4 (FABP4) protects against renal ischemia-reperfusion injury","volume":"8","author":"Shi","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejphar.2020.173570_bib28","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.2174\/0929867325666181008154622","article-title":"Role of fatty acid binding protein 4 (FABP4) in kidney disease","volume":"27","author":"Shi","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173570_bib29","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1111\/jcmm.14512","article-title":"Pharmacological and genetic inhibition of fatty acid-binding protein 4 alleviated cisplatin-induced acute kidney injury","volume":"23","author":"Tan","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2020.173570_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000368412","article-title":"Ectopic expression of fatty acid-binding protein 4 in the glomerulus is associated with proteinuria and renal dysfunction","volume":"128","author":"Tanaka","year":"2014","journal-title":"Nephron Clin. Pract."},{"key":"10.1016\/j.ejphar.2020.173570_bib31","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41581-019-0110-2","article-title":"Macrophages: versatile players in renal inflammation and fibrosis","volume":"15","author":"Tang","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2020.173570_bib32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.kint.2018.05.022","article-title":"JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis","volume":"94","author":"Tao","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2020.173570_bib33","doi-asserted-by":"crossref","first-page":"F660","DOI":"10.1152\/ajprenal.00480.2018","article-title":"Blockade of ERK1\/2 by U0126 alleviates uric acid-induced EMT and tubular cell injury in rats with hyperuricemic nephropathy","volume":"316","author":"Tao","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2020.173570_bib34","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.foodchem.2012.04.026","article-title":"Protection of curcumin against fructose-induced hyperuricaemia and renal endothelial dysfunction involves NO-mediated JAK-STAT signalling in rats","volume":"134","author":"Zhang","year":"2012","journal-title":"Food Chem."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920306622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920306622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:43:07Z","timestamp":1757976187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920306622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":34,"alternative-id":["S0014299920306622"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173570","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173570"}}